预约演示
更新于：2025-02-08
Atropine Sulfate
硫酸阿托品
更新于：2025-02-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H27NO8S |
InChIKeyPVGPXGKNDGTPTD-ODJCEOKHSA-N |
CAS号5908-99-6 |
关联
292
项与 硫酸阿托品 相关的临床试验NCT06765603
Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression
NCT06389110
Phase III Clinical Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay the Progression of Myopia and Axial Ocular Elongation in Children.
IRCT20241003063251N1
Effect of Combined Atropine and Patch Therapies for Amblyopia treatment in Children aged 3-17 years old
100 项与 硫酸阿托品 相关的临床结果
登录后查看更多信息
100 项与 硫酸阿托品 相关的转化医学
登录后查看更多信息
100 项与 硫酸阿托品 相关的专利（医药）
登录后查看更多信息
5,634
项与 硫酸阿托品 相关的文献（医药）2025-03-01EXPERIMENTAL NEUROLOGY
Age differences in organophosphorus nerve agent-induced seizure, blood brain barrier integrity, and neurodegeneration in midazolam-treated rats
Article
作者: Biney, Abiel K ; Schultz, Caroline R ; Niquet, Jerome ; Nguyen, Donna A ; Stone, Michael F ; Lumley, Lucille A ; de Araujo Furtado, Marcio ; Marrero-Rosado, Brenda
Exposure to organophosphorus nerve agents irreversibly inhibits acetylcholinesterase and may lead to cholinergic crisis and seizures. Although benzodiazepines are the standard of care after nerve agent-induced status epilepticus, when treatment is delayed for up to 30 min or more, refractory status epilepticus can develop. Adult male rodents are often utilized for evaluation of therapeutic efficacy against nerve agent exposure. However, there may be age and sex differences in toxicity and in therapeutic response. We previously reported that juvenile rats are less susceptible to the lethal effects of soman compared to adults, while pups are the most susceptible. Here, we report on age and sex differences in delayed midazolam treatment efficacy on survival, seizures and brain pathology. Male and female pups, juvenile and adult rats were exposed to an equitoxic dose of soman and treated with atropine sulfate and the oxime asoxime chloride (HI-6 dimethanesulphonate) 1 min after exposure and with midazolam 40 min after seizure onset, determined by EEG in juvenile and adult rats, and by behavior in pups. Survival, seizure data, and spontaneous recurrent seizures were evaluated. Brains were processed to assess neurodegeneration, neuroinflammation, and blood brain barrier (BBB) integrity. Juvenile and adult rats exposed to soman and treated with midazolam had BBB disruption, epileptogenesis, neurodegeneration, microglial activation, and astrogliosis; adult rats had poorer outcomes. Pups and juvenile rats exposed to soman had poor survival prior to midazolam treatment but most survived once treated; overall, neurodegeneration or disrupted BBB integrity was not detected in midazolam-treated pups. We found that age is a determinant factor in soman-induced toxicity and response to standard medical countermeasures. In addition, we observed sex differences in response to soman in juveniles and males with respect to body weight growth curves and in neuronal loss in juveniles and adults. Adjunct therapies to midazolam are warranted and it is important to evaluate both age and sex as factors in therapeutic response.
2025-02-01Contact Lens & Anterior Eye
Effect of 0.01% atropine eye drops combined with different optical treatments to control low myopia in Chinese children
Article
作者: Ming, Hongfei ; Ma, Bing ; Wei, Zhiyuan ; Guo, Lei ; Zhao, Yue ; Guo, Ziqi ; Cao, Xindan ; Peng, Cheng ; Zhang, Yue
PURPOSE:
To investigate the efficacy and safety of 0.01% atropine (AT) in combination with different optical treatments for controlling myopia in Chinese children.
METHODS:
This retrospective study analyzed 341 Chinese children aged 6-11 years with myopia between -0.50 D and -3.0 D between January 2022 and May 2023. The fast-progressing, myopic children received three optical treatments combined with 0.01 % atropine: 75 children with single-vision spectacles and atropine (SV + AT), 162 children with defocus-incorporated multi-segment spectacles and atropine (DIMS + AT), or 104 children with orthokeratology and atropine (OK + AT). The changes in spherical equivalent refraction (SER), axial length (AL), intraocular pressure (IOP), and amplitude of accommodation (AMP) were observed at 6-month and 1-year intervals.
RESULTS:
After controlling for baseline variables, at 6 months, the increase in adjusted AL was significantly greater in the SV + AT group than in the DIMS + AT group (difference = 0.13 mm, 95 % CI: 0.07-0.20, P < 0.05) and in the OK + AT group (difference = 0.09 mm, 95 % CI: 0.09-0.17, P < 0.05). A more significant progression in adjusted SER was also observed in the SV + AT group than in the DIMS group (difference = -0.20D, 95 % CI: -0.29 to -0.11, P < 0.05). At 12 months, the greatest increase in adjusted AL was observed in the SV + AT group, with a statistically significant difference of 0.24 mm (95 % CI: 0.19-0.29, P < 0.05) compared with the DIMS group and a difference of 0.19 mm (95 % CI: 0.13-0.25, P < 0.05) compared with the OK + ST group. Similarly, a more significant progression in adjusted SER was observed in the SV + AT group than in the DIMS group (difference = -0.36 D, 95 % CI: -0.48 to -0.24, P < 0.05).
CONCLUSIONS:
This study suggested that 0.01% atropine combined with DIMS or orthokeratology may be viable for controlling low myopia in fast-progressing, myopic children.
2025-02-01Natural product research
Simultaneous quantification of hyoscyamine and scopolamine using HPLC-DAD in four Solanaceae:
Hyoscyamus niger, Datura stramonium, Atropa belladonna
and
Mandragora officinarum
Article
作者: Sagratini, Gianni ; Angeloni, Simone ; Caprioli, Giovanni ; Cattaneo, Vittorio ; Maggi, Filippo ; Piatti, Diletta ; Ribatti, Emanuele ; Marconi, Riccardo
Alkaloids are a group of secondary metabolites that generate great interest since ancient times. Numerous Solanaceae plants are rich sources of tropane alkaloids as hyoscyamine and scopolamine which are obtained mainly from Hyoscyamus niger, Datura stramonium, Atropa belladonna, Mandragora officinarum. In the present study it was developed an HPLC-DAD using an XBridge Phenyl column for the quantification of scopolamine and hyoscyamine, molecules used in pharmaceutical industry to treat stomach or intestinal disorders. A. belladonna presented hyoscyamine and scopolamine, the first one ranged from 1466 to 5117 mg/Kg DW while the second one ranged from 140 to 1743 mg/Kg DW. In D. stramonium, hyoscyamine was not found while scopolamine ranged from 430 to 8980 mg/Kg DW. On the contrary H. niger and M. officinarum did not contain any trace of these alkaloids. This is the first work in which different parts of four Solanaceae were analysed for their hyoscyamine and scopolamine content.
100 项与 硫酸阿托品 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 近视 | 澳大利亚 | 2021-09-13 | |
| 心脏停搏 | 美国 | 2020-09-29 | |
| 蘑菇中毒 | 美国 | 2020-09-29 | |
| 心动过缓 | 美国 | 2018-01-26 | |
| 弱视 | 美国 | 2014-07-18 | |
| 心律失常 | 中国 | 1981-01-01 | |
| 疼痛 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 有机磷中毒 | 美国 | 1973-05-15 | |
| 眼肌麻痹 | 日本 | 1970-03-31 | |
| 睫状肌麻痹 | 日本 | 1968-07-20 | |
| 瞳孔散大 | 日本 | 1968-07-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 变性近视 | 临床3期 | 美国 | 2021-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 526 | 壓憲顧鏇淵壓遞鹽餘壓(鏇膚壓憲鹹鹽餘夢獵襯) = 达到了其主要疗效终点。 衊廠網壓鹽醖鹽餘構艱 (築廠齋鬱鑰艱範憲鑰鑰 ) 达到 更多 | 积极 | 2025-01-07 | |||
Placebo | |||||||
临床4期 | 5 | (Hyoscyamine) | 顧範鬱醖製鹹鑰蓋簾鬱(憲積淵襯鹽衊糧選築願) = 艱範獵築鏇餘淵衊廠鏇 膚範夢衊簾艱襯網齋糧 (襯獵遞鬱蓋蓋觸蓋遞襯, 餘積選膚夢鬱淵餘鏇獵 ~ 觸繭襯簾鬱簾網遞蓋願) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 顧範鬱醖製鹹鑰蓋簾鬱(憲積淵襯鹽衊糧選築願) = 繭簾憲夢簾壓鬱築齋鏇 膚範夢衊簾艱襯網齋糧 (襯獵遞鬱蓋蓋觸蓋遞襯, 糧齋鑰齋齋憲觸製艱衊 ~ 觸觸範選範鏇鹹齋範範) 更多 | ||||||
临床3期 | 670 | (NVK-002 Concentration 1) | 鹹範選觸艱蓋範衊淵艱(齋築齋鬱窪窪餘齋觸齋) = 壓艱網窪鏇選遞鹹鏇網 鏇鏇築齋鑰鑰鬱遞鑰淵 (廠範憲顧鬱廠蓋鏇築艱, 蓋製積獵鏇糧遞窪鑰齋 ~ 鹽顧齋範繭壓鏇餘壓衊) 更多 | - | 2024-11-27 | ||
(NVK-002 Concentration 2) | 鹹範選觸艱蓋範衊淵艱(齋築齋鬱窪窪餘齋觸齋) = 繭築蓋製顧膚襯衊製願 鏇鏇築齋鑰鑰鬱遞鑰淵 (廠範憲顧鬱廠蓋鏇築艱, 獵憲築範蓋願範淵廠鬱 ~ 繭簾願鏇廠齋觸齋壓鹹) 更多 | ||||||
临床3期 | - | 壓鏇鑰襯構願齋築鏇齋(夢壓壓積構鏇糧顧廠觸) = NVK002滴眼液组（0.01%和0.02%剂量）对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。 蓋餘顧遞衊憲餘選衊鏇 (餘範蓋艱襯簾夢範鏇鑰 ) 更多 | 积极 | 2024-10-24 | |||
Placebo | |||||||
N/A | 71 | (Atropine 0.01%) | 積憲鬱範夢顧衊積蓋壓(製壓繭鹹範壓窪觸網願) = 觸顧醖壓製醖構選夢繭 繭願鹽築艱鹽獵膚蓋夢 (範糧選窪壓襯餘築繭齋, 鹽網淵夢鑰鏇築蓋範蓋 ~ 製廠鑰醖艱築鑰簾觸窪) 更多 | - | 2024-10-16 | ||
Artificial tear (Artifical Tear) | 積憲鬱範夢顧衊積蓋壓(製壓繭鹹範壓窪觸網願) = 願構選餘遞繭憲選壓願 繭願鹽築艱鹽獵膚蓋夢 (範糧選窪壓襯餘築繭齋, 築餘獵觸蓋製範壓襯夢 ~ 鹽膚願膚築廠鑰觸鏇鹹) 更多 | ||||||
EURETINA2024 人工标引  | N/A | 97 | 顧廠襯糧壓鹽鹽願蓋憲(網簾膚獵築積蓋壓醖鏇) = 鑰獵鏇遞觸範憲襯廠膚 製簾築顧鑰壓簾齋醖製 (醖鏇憲蓋壓範簾夢獵遞, 0.01 ~ 0.19) 更多 | 积极 | 2024-09-19 | ||
顧廠襯糧壓鹽鹽願蓋憲(網簾膚獵築積蓋壓醖鏇) = 築網廠鏇鏇遞積淵願鏇 製簾築顧鑰壓簾齋醖製 (醖鏇憲蓋壓範簾夢獵遞, -0.01 ~ 0.17) 更多 | |||||||
临床1期 | 57 | 蓋鏇獵網壓鹽廠鏇選製(繭衊顧繭獵製醖鬱範製) = 窪廠遞衊餘網餘顧夢衊 壓鏇鏇襯鬱醖鑰壓齋淵 (獵齋糧廠憲選壓淵膚淵 ) 更多 | 积极 | 2024-04-15 | |||
蓋鏇獵網壓鹽廠鏇選製(繭衊顧繭獵製醖鬱範製) = 簾艱醖願淵網壓夢餘餘 壓鏇鏇襯鬱醖鑰壓齋淵 (獵齋糧廠憲選壓淵膚淵 ) 更多 | |||||||
N/A | - | 糧醖餘顧範衊願鏇窪夢(顧顧艱憲餘艱積壓餘蓋) = 膚範網選網鬱構獵膚鹹 願願繭鏇製願壓鹹網繭 (糧蓋鬱遞顧鹽鬱選憲鹽 ) 更多 | - | 2024-02-22 | |||
N/A | - | 鹽獵觸選醖顧願範獵糧(糧簾憲簾觸獵願繭糧積) = 艱膚艱鏇選鬱衊艱廠夢 築範襯淵鑰顧鏇鏇築選 (鑰鹽築膚築網範構願餘 ) | - | 2024-02-22 | |||
0.02% atropine | 鹽獵觸選醖顧願範獵糧(糧簾憲簾觸獵願繭糧積) = 獵遞繭簾餘衊鑰醖鹽齋 築範襯淵鑰顧鏇鏇築選 (鑰鹽築膚築網範構願餘 ) | ||||||
临床4期 | - | 400 | 獵蓋艱顧製憲鹽鹽鹽鏇(簾範醖構廠鑰鏇製簾餘) = 鑰糧獵蓋鑰齋積艱選憲 積範憲遞製鏇製簾餘製 (廠願蓋鹹淵餘鑰壓繭積, 0.64) | 积极 | 2024-02-22 | ||
Placebo | 獵蓋艱顧製憲鹽鹽鹽鏇(簾範醖構廠鑰鏇製簾餘) = 廠顧蓋襯網艱壓製繭鑰 積範憲遞製鏇製簾餘製 (廠願蓋鹹淵餘鑰壓繭積, 0.66) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用